Serum Lactate in Acute Mesenteric Ischemia

Lactate Dehydrogenase, Bowel Necrosis and Mortality in Acute Mesenteric Ischemia: Retrospective Cross-Sectional

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04671979

Enrollment

Registered

2020-12-17

Start date

2017-05-02

Completion date

2020-06-30

Last updated

2020-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mesenteric Ischemia

Keywords

Biomarker, L-Lactate, Mortality

Brief summary

Background: Acute mesenteric ischemia is a vascular emergency with high mortality because of ambiguous symptomatology and a lack of early diagnostic markers. Lactate dehydrogenase has been described as a mortality biomarker and bowel necrosis length too. Nevertheless, the association between them has been mildly studied. Our objective was to evaluate the association between serum lactate admission levels, bowel necrosis extension, and mortality. Additionally, we performed a mortality characterization. Materials and Methods: A retrospective cross-sectional study was designed. We reviewed patients' clinical records with acute mesenteric ischemia that attended a hospital between 2012 and 2018. We compared serum lactate admission levels with bowel necrosis length and mortality. A receiver operating characteristic curve was performed on the last association. As post hoc analysis, a classification and regression tree on mortality was fitted.

Interventions

DIAGNOSTIC_TESTLactate Dehydrogenase

All the patients that arrived at the hospital with symptoms of mesenteric ischemia, had a registered lactate dehydrogenase. We compared the value with the patient's outcomes.

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Older than 18 years of age * Required urgent laparotomy with a postoperative diagnosis of acute mesenteric ischemia * Attended the private academic hospital, between 2012 and 2018 * Had a registered serum lactate dehydrogenase at admission

Exclusion criteria

* Secondary causes of AMI * Chronic intestinal ischemic * Patient records with no description of the serum lactate dehydrogenase or extension of intestinal necrosis

Design outcomes

Primary

Measure	Time frame
Serum Lactate in mmol/l	30 days
Bowel necrosis length in cm	30 days
Percentage of patients that died between 30 postsurgical days, %	30 days

Secondary

Measure	Time frame	Description
Cut value of lactate levels as a predictor of mortality, in mmol/l	30 days	A receiver operating characteristics curve

Countries

Colombia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026